WO1999060402A1 - Ligand binding assay and kit with a separation zone for disturbing analytes - Google Patents

Ligand binding assay and kit with a separation zone for disturbing analytes Download PDF

Info

Publication number
WO1999060402A1
WO1999060402A1 PCT/SE1999/000722 SE9900722W WO9960402A1 WO 1999060402 A1 WO1999060402 A1 WO 1999060402A1 SE 9900722 W SE9900722 W SE 9900722W WO 9960402 A1 WO9960402 A1 WO 9960402A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
reactant
zone
ligand
component
Prior art date
Application number
PCT/SE1999/000722
Other languages
French (fr)
Inventor
Jan Carlsson
Maria LÖNNBERG
Original Assignee
Pharmacia & Upjohn Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Diagnostics Ab filed Critical Pharmacia & Upjohn Diagnostics Ab
Priority to DE69936916T priority Critical patent/DE69936916T2/en
Priority to CA2330100A priority patent/CA2330100C/en
Priority to JP2000549963A priority patent/JP4579414B2/en
Priority to AU43036/99A priority patent/AU758583B2/en
Priority to US09/673,882 priority patent/US6737278B1/en
Priority to EP99952122A priority patent/EP1075661B1/en
Publication of WO1999060402A1 publication Critical patent/WO1999060402A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/97—Test strip or test slide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/81—Tube, bottle, or dipstick
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample

Definitions

  • Sandwich technique usually means that an analytically detectable complex is formed in which the analyte binds to two bioaffine counterparts, one of which is analytically detectable and the other is Capturer
  • the analyte and an analytically detectable analyte analogue will compete for a limiting amount of bioaffine counterpart
  • two competitive va ⁇ ants may be mentioned those that use a) competition between analyte and analyte analogue, which is labelled, for a limiting amount of hgand m the form of a firmly anchored Capturer, and b) competition between analyte and analyte analogue in the form of firmly anchored Capturer for a limiting amount of soluble and analytically detectable bioaffine counterpart
  • Heteroforms may be isoforms of proteins, e g lsoenzymes etc Within the term heteroforms are included inter aha different forms of bioaffine complexes which "resemble" each other by meeting the above definition Examples are immunocomplexes where the antigen is the same but the antibody is of different class/subclass See further under the title "Analyte” below
  • the components of a sample that may affect or influence the signal that is to be detected m DZ can be divided into two mam groups a) the analyte and b) components which directly or indirectly disturb the detection
  • Directly disturbing components are those which interfere with the signal as such, for example fluorescent components in serum in case the complex is to be detected by fluorescence
  • indirectly disturbing components are heteroforms with regard to Capturer and/or an added bioaffine reactant R (for example R*)
  • Other indirectly disturbing components for example heterophihc antibodies, may be present m the o ⁇ gmal sample and interfere with the formation of the signal complex m DZ
  • the hgands that are released from the separation zone of the invention may act disturbingly (see Example 1) Problems with disturbing components in samples have often meant that for analytes that are present in low concentrations, the separation of disturbing components and the detection have been performed m different systems
  • WO 94/06012 discloses an analytical test apparatus having a negative control zone placed before the analyte detection zone The negative control zone has the function to indicate the presence m the sample of components that affect the analyte detection so that it becomes unreliable
  • the flow mat ⁇ x contains one or more separation zones (SZ) between ASZ and DZ, which should permit at least one component, capable of influencing the signal from the signal complex in DZ, to be retarded/separated This should take place in SZ by means of the ligand interactions mentioned below, which can be reversible or irreversible
  • the component may be either a disturbing component or the analyte If the component is not an analyte, the retardation means that the component (or components) migrates more slowly than the analyte through SZ or is bound irreversibly to SZ and thereby is prevented from reaching DZ such that the detection of analyte in DZ essentially will not be disturbed by the component (or components) in question Usually, this means that there should be a sufficient amount of ligand for substantially all of the disturbing component or components in the sample to be affected "Substantially all" depends on the relative concentrations of the component(
  • the formation of signal complexes will take place m the absence thereof
  • the detection of signal complexes in DZ may be taken as a qualitative or quantitative measure of the analyte
  • the point of time for the formation of a signal complex will be changed, or, if the analyte-hgand binding in SZ is irreversible, the formation of a signal complex may be completely inhibited
  • the formation of a signal complex in DZ will be a measure of the capability of the analyte to bind to the ligand m SZ
  • Figure 2B is the same as the va ⁇ ant in Figure 2A except that ARZ and ASZ coincide
  • the Capturer m the detection zone may be selected according to the same rules as those applying to the ligand in the separation zone, with the proviso that the binding capability of the Capturer should be directed towards the analyte and/or towards an analyte-related reactant. It is advantageous to choose highly affine Capturers with rapid kinetics for capture of the ligand It is p ⁇ ma ⁇ ly of interest to use antibodies or antigen hapten for which it is often easy to find highly affine antibodies.
  • analyte-related reactant is intended a reactant (R) that is added and when migrating through DZ may bind to the Capturer m an amount that is related to the presence of analyte m the sample.
  • R reactant
  • Examples of analyte-related reactants are R* in the form of a) labelled analyte analogue m competitive methods that use competition for a limiting amount of solid-phase-bound anti-analyte antibody, and b) labelled or non- labelled soluble anti-analyte antibody m methods that use competition/inhibition between sohd-phase-bound analyte analogue and analyte for a limiting amount of anti- analyte antibody m dissolved form.
  • analyte is intended the compound or compounds that are determined quantitatively or qualitatively Quantitative determination relates to the measurement of quantities in absolute as well as relative terms
  • Qualitative determination of an analyte refers to detecting the existence or non-existence of something (yes/no test) or qualitative properties of a compound, such as capability of affimty-bmding to a certain ligand
  • the measurement value obtained is a ratio of the sum of one or more selected heteroforms and the sum of another combination of heteroforms
  • An example is the ratio of analyte amount and total amount of all heteroforms with regard to a certain counterpart (total amount includes the amount of analyte)
  • the analyte will be the inactive enzyme.
  • Proteins, peptides or other biomolecules which exert their biological function by binding to a specific receptor could be separated by means of a ligand in SZ which is a receptor for the biomolecule.
  • the analyte will be the fraction of the molecules that lack or have a reduced capability of binding to the receptor.
  • Proteins e.g. IgE
  • Degradation isoforms of proteins where ammo acids have been cleaved off can be determined by the invention
  • degradation isoforms of creatine kinase (CK) are interesting cardiac markers
  • Labelled antigen hapten has its p ⁇ mary use in A) competitive techniques m which a labelled antigen hapten is allowed to compete with an unlabelled antigen/hapten for a limiting amount of antibody
  • va ⁇ ants of the invention which an analytically detectable reactant (R*) is not utilized are those where the analyte per se is detectable when it is part of the complex m DZ
  • enzyme as analyte m combination with a substrate that gives an analytically detectable product, for example a substrate that gives a coloured or fluorescent product that should be insoluble R* may, but need not, exhibit binding capability to the disturbing components that are separated in SZ
  • the application zone thereof should be located downstream of the separation zone (SZ), unless it is desired to measure the level of disturbing heteroforms by means of the amount of R* binding to SZ.
  • a particularly useful labelling group is particles which optionally contain one of the above mentioned detectable groups, such as fluoropho ⁇ c group or chromogemc group (fluorescent and coloured particles, respectively).
  • detectable groups such as fluoropho ⁇ c group or chromogemc group (fluorescent and coloured particles, respectively).
  • Useful particles often have a size in the range of 0 001 to 5 ⁇ m, with preference for the range of 0 05 to 5 ⁇ m
  • the particles may be of colloidal dimensions, so-called sol (i.e. usually sphe ⁇ cal and monodisperse having a size in the range of 0.001 to 1 ⁇ m).
  • metal particles for example, gold sol
  • non-metal particles for example, SiCb, carbon, latex and killed erythrocytes and bacte ⁇ a
  • particles of non-colloidal dimensions have been used These particles have been more or less irregular and more or less polydisperse (for example, carbon particles ⁇ 1 ⁇ m, Pharmacia AB, WO 96/22532)
  • the complex in DZ may often be detected visually or by optical measu ⁇ ng equipment (e g a CCD camera coupled to a computer with special software for image analysis or a laser scanner)
  • optical measu ⁇ ng equipment e g a CCD camera coupled to a computer with special software for image analysis or a laser scanner
  • Figure 2A The variant according to this figure has five separation zones (SZ) in which the ligand may be the same or different or be present in different amounts (15-19) and an AR*Z (20) for reagents.
  • SZ separation zones
  • AR*Z AR*Z
  • IgA, IgG and IgM Free IgE and IgE complex-bound to autoantibody
  • IgA, IgG and IgM may be of interest to measure. Above all, however, free IgE should be quantified correctly.
  • the autoantibodies may bind to the same epitopes on IgE as the reagent antibodies (anti-IgE antibody) and this may then give rise to falsely too low total IgE levels that vary depending on the design of the test. By separating IgG, IgM and IgA before the measurement of IgE, free IgE may be detected.
  • the amount of autoantibodies should also be quantified both as complexes and as free IgG antibodies directed against IgE.
  • IgG When measu ⁇ ng IgG-complex bound IgE, IgG is captured to a solid phase s (corresponding to DZ) which supports covalently bound anti-IgG antibody (Capturer) By adding labelled anti-IgE antibody (R*), the amount of complex-bound IgE may be measured
  • Separation membrane 1 Sheep anti-mouse IgG(Fc) (Ligand 1) was coupled to polystyrene aldehyde particles (0.29 ⁇ m diameter, IDC, Portland, Oregon, U.S.A.) by mixing 1.0 mg/ml of antibodies and 20 mg/ml of polystyrene aldehyde particles in 25 mM phosphate buffer, pH 6.6, at +4°C for 20 hours. The particles were washed in 20 mM borate buffer, pH 8.6, and were reacted with 15 mg of NaCNBH3 (Sigma-Aldrich Chemie, Steinheim, Germany) per 50 mg of particles for 20 hours.
  • NaCNBH3 Sigma-Aldrich Chemie, Steinheim, Germany
  • the particles were then washed in 20 mM borate buffer, pH 8.6, by repeated suspension, centrifugation and decanting.
  • the particle suspension was diluted in 3% trehalose, 20 mM borate buffer, to 25 mg of particles/ml.
  • the diluted suspension was sprayed on strips (20 cm x 3 cm) of membranes of nitrocellulose (nitrocellulose on polyester, 5 ⁇ m pore size, Whatman International Ltd, England) in two 0.3 cm wide lines which were parallel to the long sides of the strips.
  • the spraying equipment (IVEK linear striper, IVEK Corporation, Vermont, U.S.A.) delivered about 50 ⁇ g of polystyrene particles/cm for each line.
  • the membranes were dried at room temperature and then cut to smaller pieces (0.5 cm x 3 cm).
  • Detection membrane Mouse anti-IgE monoclonal antibody (directed against domain 4 on IgE, Capturer) was diluted in 20 mM borate buffer to 1.0 mg of protein ml. The diluted antibody was sprayed on strips (20 cm x 4 cm) of membranes of nitrocellulose (the same type as above) in a 0.15 wide line (spraying equipment as above) with about 1 ⁇ g of antibodies/cm. The membranes were dried at room temperature and then cut to smaller pieces (0.5 cm x 4 cm) so that the line with antibody was parallel with a short side.
  • DZ Detection membrane
  • Combination membrane See Figure 3.
  • the pieces were kept together on the bottom side by adhesive tape.
  • On the top side were placed pieces of nitrocellulose (0.5 cm x 0.3 cm) (A100, 12 ⁇ m, Schleicher and Schull, Dassel, Germany) which somewhat overlapped two adjacent short sides. The latter pieces were kept in place by more adhesive tape.
  • Carbon suspension (stock solution) 2 g of carbon particles (sp 100, Degussa, Germany) were suspended in 200 ml of 5 mM borate buffer, pH 8.4, and sonicated (VibraCell 600 W, 1.5 cm probe, Soniced Materials, Danebury, Connecticut, U.S.A.) in an ice-bath for 3 x 5 minutes at 100 % amplitude and with 9.9 + 2 seconds pulse.
  • Bovine serum albumin (BSA) was added to 1 % and the particles were mixed for another 30 minutes and then washed by means of centrifugation in 1 % BSA (0.1 M borate buffer, pH 8.5, 0.05 % NaN3) and diluted to 0.8 mg carbon ml in the wash buffer.
  • BSA Bovine serum albumin
  • the standards (IgE) gave the same intensity on the blackening curve m both measu ⁇ ng systems
  • the complexes (IgE-IgG and IgG-IgE-IgG) were detected by a strong black signal m DZ if SZ 1 was replaced by nitrocellulose without ligand If SZl contained anti-mouse IgG as ligand, no signal could be detected in DZ for the complexes
  • modified membranes to interact with charged proteins was confirmed by transporting F25 ⁇ _ ⁇ a b e ⁇ e ⁇ ' proteins (bovine serum albumin, tetrasialo- and asialo-transferrin which had been labelled by the Chloramine T method) in a lateral liquid flow in strips of the sheet.
  • the protein having the highest pi had the strongest tendency to migrate with the liquid flow. If the liquid in different tests contained an increasing concentration of NaCl (0-1000 mM), the migration rate was affected most for the proteins having the lowest pi. Both these function controls support the fact that positively charged groups had been introduced in the treatment with polyethylene imine, and that these groups can function as ion-exchanging groups towards protein and NaCl.
  • Anti-transferrin monoclonal antibody was coupled to polystyrene-aldehyde particles (0.29 ⁇ m diameter, IDC, Portland, Oregon, U.S.A.) by mixing 1.3 mg/ml antibody and 22 mg/ml polystyrene-aldehyde particles in 25 mM phosphate buffer, pH 6.6, at +4°C for 18 hours. The particles were washed in 20 mM borate buffer, pH 8.4, and were reacted with 5 mg of NaCNBH 3 (Sigma- Aldrich Chemie GmbH, Steinheim, Germany) per 40 mg of particles per ml for 18 hours.
  • NaCNBH 3 Sigma- Aldrich Chemie GmbH, Steinheim, Germany
  • the particles were washed in 20 mM borate buffer, pH 8.6, and diluted in 20 mM borate buffer containing 6 % trehalose to 14 mg particles/ml.
  • the diluted suspension was sprayed on strips (20 cm x 4 cm) of membranes of nitrocellulose (5 ⁇ m, nitrocellulose on polyester backing, Whatman International Ltd. England) in a 1.4 mm wide line in the middle of the strip and in parallel with the long side of the strip.
  • the spraying equipment was the same as in Example 1 and now delivered 14 ⁇ g of polystyrene particles/cm.
  • the membranes were dried at room temperature and stored in a plastic bag at +4°C.
  • Combination membrane See Figure 1.
  • Carbon suspension (stock solution) 2 g of carbon particles (sp 4, Degussa, Germany) were suspended in 100 ml of 5 mM borate buffer, pH 8 4, and sonicated with the same apparatus as in Example 1 in an ice-bath for 5 minutes at 100 % amplitude and 5 + 5 seconds pulse
  • Serum samples 11 serum samples and 6 serum controls were diluted 1/50 in 20 mM BIS-TRIS pH 6.3 containing 0.1 % bovine gammaglobulin (Sigma, St Louis, U.S.A.), 0.1 % Tween 20, 0.1 mM Fe 3+ -citrate, 1 mM NaHC0 , and 0.05 % NaN 3 .
  • the serum samples were previously analysed with regard to CDT by means of CDTect (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). CDTect measures CD- transferrin.
  • a lateral liquid flow was initiated by placing a 0.6 cm x 0.6 cm x 0.3 cm cellulose sponge (8 in Figure 1) soaked with 20 mM BIS-TRIS buffer, pH 6.5, containing 15 mM NaCl and 0.1 % Tween 20 on the free end of the separation zone.
  • the analyte (CD-transferrin) and its heteroforms (other transferrins) are attracted by positive charges firmly anchored in the zone (Ligand introduced in the PEI treatment) so that a heteroform having a greater negative charge (other transferrins) is attracted more than a heteroform having a smaller negative charge (CD-transferrin), i.e. CD- transferrins migrate easier with the liquid flow than trisialo-, tetrasialo-, pentasialo- etc transferrin.
  • a sheet (4 cm x 12 cm) of cellulose (cellulose filter 54, Whatman International Ltd, England) was activated with cyano-diethyl-aminopyridine (CDAP) (Kohn and Wilchek, Appl. Biochem. Biotechnol. 9 (1984) 285-304).
  • CDAP cyano-diethyl-aminopyridine
  • the activated sheet was placed in a solution of 0.1 mg/ml of Sambucus Nigra lectin (binds sialic acid which is in the terminal position of a carbon chain; Vector Laboratories Inc., Burlingame. CA, U.S.A.) in 0.1 M NaHC0 3 , pH 8.4.
  • the sheet was mounted to self-adhering plastic (75 ⁇ m self-adhering polyester film; Gelman Science Inc, Ann Arbor, MI, U.S.A.).
  • self-adhering plastic 75 ⁇ m self-adhering polyester film; Gelman Science Inc, Ann Arbor, MI, U.S.A.
  • Membranes with detection zone and combination strip These membranes can be produced in analogy with Example 2. See also Figure 1. The ligand in SZ is now lectin.
  • Tetrasialo- and asialo-transferrin and bovine albumin were labelled with 125 ⁇ (Chloramine T, labelling degree 0.08-0.13).
  • the labelled proteins were diluted in 10 mM BIS-TRIS pH 6.4 containing 0.1 % Tween 20, 0.04 mM Fe 3+ -citrate and 0.05 % NaN 3 to about 0.3 ⁇ g/ml. Additionally, 0.4 mg BSA/ml was added.
  • a (0.5 cm x 4 cm) strip of the separation membrane and a piece of a sucking membrane of cellulose (0.5 cm x 2 cm, GB004, Schleicher and Schuell, Dassel, Germany) were joined by tape on the underside so that their ends overlapped somewhat.
  • 1 ⁇ l of the solutions of the 125j_ ⁇ a b e ⁇ ec j proteins were applied at 1 cm from the free end of a respective separation membrane.
  • the lateral flow was initiated by placing a cellulose sponge (0.6 cm x 0.6 cm x 0.3 cm) on the free end of the separation membrane.
  • the sponge was soaked with 20 mM TRIS-HCL buffer, pH 7.5, containing 0.5 M NaCl, 1 mM CaCl2 with 0.1 % Tween 20.
  • the flow was interrupted by removing the cellulose sponge after 2, 4, 6 and 10 minutes, respectively, and the membranes were cut 2 and 3 cm from the free end of the separation membrane.
  • the radioactive membrane pieces were measured in a gamma counter and the proportion of added 125j_ protein that had passed 2 and 3 cm was calculated. The values for migration of 1 cm or more is shown in Table 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The invention relates to a method for determining an analyte by means of binding reactions, which method comprises: i) applying the sample to an application zone for sample (ASZ) on a flow matrix in which transport of components present in the sample can take place (transport flow), the flow matrix further exhibiting: a) optionally an application zone (AR*Z) for a binding reactant (Reactant* = R*) which is analytically detectable; b) a detection zone (DZ), which is located downstream of ASZ and exhibits an additional binding reactant (Capturer) firmly anchored to the matrix, and in which a complex (signal complex) containing the Capturer and the analyte and/or Reactant* is formed during the reaction, and ii) detecting the signal complex in the detection zone, the measured signal being used for determining the analyte. According to the invention, the flow matrix comprises at least one separation zone (SZ) between ASZ and DZ, which zone exhibits a structure (ligand) having binding capability for a component that is transported in the matrix and which would affect the measurable signal if the component is transported into DZ. The invention also relates to a test kit comprising the flow matrix.

Description

LIGAND BINDING ASSAY AND KIT WITH A SEPARATION ZONE FOR DISTURBING ANALYTES.
Technical field of the invention
The invention relates to a method for determining an analyte in a sample and to a kit for use in the method.
Starting from the prior art, the method of the invention comprises the steps: i. The sample is applied in a sample application zone (ASZ) on a flow matrix in which transport of components present in the sample may take place (transport flow). The flow matrix further comprises: a) optionally an application zone (AR*Z) for a binding reactant (Reactant* = R*) which is analytically detectable, b) a detection zone (DZ) which is located downstream of ASZ and exhibits another binding reactant (Capturer) firmly anchored to the matrix and in which a complex (signal complex) containing the Capturer and the analyte and/or the Reactant* is formed in the method. ii. The flow is allowed to effect the transport of sample components. iii. The signal complex is detected in the detection zone and the measured signal is used for the determination of the analyte.
The invention is primarily directed to the flow matrix which may be of the same type as those previously used in, for example, immunochromatography, see below.
Suitable binding reactants are those which participate in so-called affinity reactions, especially biospecific affinity reactions, and covalent binding reactions, especially exchange reactions between free thiol and reactive disulphide and other reactions between soft electrophiles and soft nucleophiles. Common biospecific affinity reactions are immunochemical, i.e. between antibody and antigen or hapten. Other types of bioaffine reactions are hybridization between complementary nucleic acids (including oligonucleotides), reaction between lectin and carbohydrate structure, between Ig(Fc)- structure and Ig(Fc)-binding protein, such as protein A or protein G, etc. The bioaffine reactions include the reaction between a biomolecule and a synthetically prepared ligand/capturer.
For the type of method in question, one talks about non-competitive methods, for example sandwich technique, and competitive methods. Sandwich technique usually means that an analytically detectable complex is formed in which the analyte binds to two bioaffine counterparts, one of which is analytically detectable and the other is Capturer In common competitive vaπants, the analyte and an analytically detectable analyte analogue will compete for a limiting amount of bioaffine counterpart As examples of two competitive vaπants may be mentioned those that use a) competition between analyte and analyte analogue, which is labelled, for a limiting amount of hgand m the form of a firmly anchored Capturer, and b) competition between analyte and analyte analogue in the form of firmly anchored Capturer for a limiting amount of soluble and analytically detectable bioaffine counterpart For further information on previously used methodology withm the technical field of the invention it is referred to US-A-4,861,711 (Behπngwerke), WO 88/08534 (Unilever), US-A-5, 120,643 and 4,740,468 (Abbott), EP-A-284,232 and US-A-4,855,240 (Becton Dickinson) and WO 96/22532 (Pharmacia AB)
Heteroforms
Compounds which can compete for the binding to a counterpart via one of the above mentioned binding reactions Heteroforms may be isoforms of proteins, e g lsoenzymes etc Within the term heteroforms are included inter aha different forms of bioaffine complexes which "resemble" each other by meeting the above definition Examples are immunocomplexes where the antigen is the same but the antibody is of different class/subclass See further under the title "Analyte" below
Determination of whether two compounds are heteroforms to each other may be made in so-called inhibition tests
Problems to be solved by the invention
The components of a sample that may affect or influence the signal that is to be detected m DZ can be divided into two mam groups a) the analyte and b) components which directly or indirectly disturb the detection Directly disturbing components are those which interfere with the signal as such, for example fluorescent components in serum in case the complex is to be detected by fluorescence Examples of indirectly disturbing components are heteroforms with regard to Capturer and/or an added bioaffine reactant R (for example R*) Other indirectly disturbing components, for example heterophihc antibodies, may be present m the oπgmal sample and interfere with the formation of the signal complex m DZ In certain embodiments of the hgands that are released from the separation zone of the invention may act disturbingly (see Example 1) Problems with disturbing components in samples have often meant that for analytes that are present in low concentrations, the separation of disturbing components and the detection have been performed m different systems
An example where after ion-exchange separation, analysis has been carried out either by immunological systems or by on-line measurement of an absorbing group (460 nm), is m the measurement of carbohydrate deficient transferπns (CDT = CD-transferπn = asialo-, monosialo- and disialo-transferπn) When CDT is present at a relatively high concentration (10"" M), both detection alternatives have been possible, but at lower concentrations of analyte, immunological measurement is required The ion-exchange chiomatography separation is controlled from an advanced and costly equipment, which requires specially educated personnel Also the traditional immunological tests are expensive and require well-educated personnel
The technique for immunological on-line measurement after a chromatographic separation step has been descπbed by Afeyan et al (Nature 358 (1992) 603-604) and Irth et al (Anal. Chem 14 (1995) 355-361) Its difficulties have been summarized by Krull et al (LC-GC 15(7) (1997) 620-629)
Transport of whole cells into DZ may interfere with the signal from the detection complex It is previously known to use flow matπces where the cells are captured mechanically (through filtration) m a denser pre-zone (Oudheusden et al., Ann. Chn Biochem. 28 (1991) 55-59) EP-A-696,735 discloses a chromatographic immunoanalytical system where, m order to extend the measuπng range for the analyte, a predetermined amount of analyte- bindmg antibody has been immobilized in the sample application zone so that a certain amount of analyte is retained therein.
EP-A-702,233 discloses a chromatographic immunoanalytical system where, in a similar manner to that described m EP-A-696,735, a dilution effect of the sample is achieved by capturing a certain amount of analyte before it reacts with labelled reactant \\ hich is then detected in the detection zone WO 97/35205 discloses a chromatographic membrane for lmmunoanalysis having (l) a zone for the detection of labelled analyte-bindmg reactant which has not bound to the analyte, and (n) a zone for the detection of the complex between analyte- bindmg reactant and the analyte The relative amounts of unbound analyte-bindmg reactant and analyte reactant complex gives a measure of the amount of analyte in the sample
WO 94/06012 discloses an analytical test apparatus having a negative control zone placed before the analyte detection zone The negative control zone has the function to indicate the presence m the sample of components that affect the analyte detection so that it becomes unreliable
Objects of the invention
A first mam object of the invention is to create a simple and rapid method that facilitates the determination of an analyte in the presence of disturbing components A particular object is to avoid problems with disturbing components that are soluble or suspendable in liquid media of interest
A second mam object of the invention is more rapid and simpler determinations of individual heteroforms or combinations thereof, especially heteroforms, that exhibit peptide, carbohydrate or hpid structures, including vaπous types of biologically active compounds Among hpids are included steroids and other fat-soluble substances
A third mam object of the invention is to facilitate the measurement of analytes in the concentration range < 10"^ M, particularly < 10"9 M, especially for samples containing disturbing heteroforms of the analyte
A fourth mam object of the invention is to simplify the determination of individual heteroforms or combinations thereof in samples originating from biological mateπals
A fifth mam object of the invention is to provide more rapid and simpler evaluations of hbraπes of compounds, for example chemical hbraπes, such as combmatoπal hbraπes A subobject of the above mentioned four mam objects is to improve the possibilities of making determinations in field environment (usually semi- quantitatively) as well as in advanced laboratoπes (with the possibility of accurate quantification)
The invention The above mentioned objects may be achieved with the method mentioned in the introductory part herein, if the flow matπx contains one or more separation zones (SZ) between ASZ and DZ, which should permit at least one component, capable of influencing the signal from the signal complex in DZ, to be retarded/separated This should take place in SZ by means of the ligand interactions mentioned below, which can be reversible or irreversible The component may be either a disturbing component or the analyte If the component is not an analyte, the retardation means that the component (or components) migrates more slowly than the analyte through SZ or is bound irreversibly to SZ and thereby is prevented from reaching DZ such that the detection of analyte in DZ essentially will not be disturbed by the component (or components) in question Usually, this means that there should be a sufficient amount of ligand for substantially all of the disturbing component or components in the sample to be affected "Substantially all" depends on the relative concentrations of the component(s), but usually means that at least 90 %, preferably at least about 95 %, and more preferably at least 99 % of the disturbing component(s) are retarded or captured m the separation zone The component may be the analyte if it is desired to study the capability of one or more hgands to bind the analyte In this case such a ligand is immobilized in the separation zone
The choice of retarding structure/hgand in the separation zone is determined by the components that are retarded The retardation may be based on vanous more or less specific interactions between the ligand structure and the component(s) to be retarded, see below under the title "Separation zone" After the passage of SZ, the analyte will migrate with the transport flow to the detection zone (DZ), in which a complex containing the Capturer and the analyte and or R* are formed
In those cases where it is intended to retard one or more disturbing components, the formation of signal complexes will take place m the absence thereof The detection of signal complexes in DZ may be taken as a qualitative or quantitative measure of the analyte In those cases where it is intended to retard the analyte, the point of time for the formation of a signal complex will be changed, or, if the analyte-hgand binding in SZ is irreversible, the formation of a signal complex may be completely inhibited The formation of a signal complex in DZ will be a measure of the capability of the analyte to bind to the ligand m SZ
Figures 1-3 illustrate different vaπants of flow matπces according to the invention
Figure 1 is a simple vanant having an ASZ, an ARZ, a SZ and a DZ ARZ and ASZ are separated Figure 2A differs from the vaπant in Figure 1 pπmaπly by having five separation zones with the same ligand ARZ and ASZ are separated
Figure 2B is the same as the vaπant in Figure 2A except that ARZ and ASZ coincide Figure 3 illustrates the vanant of flow matπx of the invention that is used in Example 1 with three separation zones, two zones (SZ1) thereof exhibiting a certain ligand and one zone (SZ2) exhibiting another ligand ASZ and ARZ (= AR*Z) are separated
A more detailed descπption of Figure 1 is given under the title "Matπx and transport flow", and of Figures 2-3 m the introduction to Example 1 The flow matπces represented by Figures 1-3 may m pπnciple have any of the geometπc embodiments below
Matrix and transport flow
The matπx is of the same type as those previously used in so-called lmmunochromatographic determination methods (flow matπx) and defines the room m which reactants and sample components are transported The matπx may thus be the internal surface of a single flow channel (for example a capillary), the internal surface of a porous matπx having a penetrating system of flow channels (porous matπx) etc The matπx may be in the form of monolith, sheet, column, membrane, separate flow channel(s), for example of capillary dimensions, or aggregated systems of such flow channels etc They may also be in the form of particles packed in column cartridges or in cut grooves, compressed fibres etc Another alternative is so-called nanocolumns for liquid chromatography, l e silicon or quartz plates having channels of about 2 μm or less prepared by microhthography (see e g He, B , et al , Anal Chem 1998, 70, 3790-3797) The inner surface of the matπx, 1 e the surface of the flow channels, should be sufficiently hydrophihc to permit aqueous media (pπmanly water) to be transported through the matrix, either by means of capillary force or by means of applied pressure or suction The smallest inner dimension of the flow channels (for round channels measured as a diameter) should be sufficiently great to permit transport through the matπx of analyte, added reactants, and components that interfere m the detection zone and that are to be retarded in SZ The rule of thumb is that suitable matπces may be selected among those with flow channels having a smallest inner dimension in the range of 0 1-1000 μm, with preference for 0 4-100 μm if the matπx has a system of communicating flow channels Flow channels having their smallest dimension in the upper part of the broad range (up to 1000 μm) are pnmaπly of interest for flows dπven by externally applied pressure/suction
Suitable matπces are often built up from a polymer, for example nitrocellulose, polyester, polyethersulphone, nylon, cellulose nitrate/acetate, cellulose, regenerated cellulose Advantageously, these membranes may be provided with a tight backside of e g polyester
The mateπal of the matπx as well as the physical and geometric design of the flow channels may vary along the flow depending on the intended use of a certain part of the matπx [WO 96/22532 (Pharmacia AB), WO 94/15215 (Medix)] One and the same matπx may compπse several transport flows that are parallel or directed radially from a common centre, for example in the form of separate channels In some of the most important embodiments, at least the detection zone and the most adjacent parts of the matπx should be in such a form that the transport flow into, in and out of DZ may take place laterally in the matπx, 1 e at least this part of the matπx is in the form of a membrane stπp or plate having cut grooves or the like
Vaπous flow matπces that may be used in the type of tests in question are descπbed in pnor patent publications See e g US-A-4,861,711 (Behπngwerke), WO 88/08534 (Unilever), US-A-5, 120,643 and US-A-4,740,468 (Abbott), EP-A-284,232 and US-A-4,855,240 (Becton Dickinson), WO 96/22532 (Pharmacia AB) The most important embodiment of the invention at the pπoπty date is based on liquid transport in a flow matπx which is in the form of e g a membrane stπp (see Fig 1) The stπp is made up of a matπx that defines a transport flow (1) and is applied to a liquid-tight backing (2), suitably of plastic On the matπx there is an appphcation zone for sample (3, ASZ) and a detection zone (4, DZ) located downstream thereof The transport flow is m the direction from ASZ towards DZ Between the sample application zone (ASZ) and the detection zone there is a separation zone (5, SZ) In the transport flow there may, if required by the particular embodiment, also be application zones (6) for additional reactants (R, for example R*, with application zone ARZ, for example AR*Z) Between said zones there may be zones (7) the only function of which is to transport reactants The position of an application zone ARZ (AR*Z) is determined by the test protocol to be used, and may be upstream or downstream of or coincide with ASZ For the case that ARZ (for example AR*Z) is upstream of ASZ, it may be advantageous if the addition of liquid in ASZ takes place substantially simultaneously as the addition of liquid m the zone ARZ (AR*Z) located upstream thereof See our earlier filed international patent application PCT/SE98/02463 (incorporated by reference herein) For certain types of test protocols, ARZ (AR*Z) may coincide with DZ
In some embodiments it is advantageous if a reactant R, for example R*, is pre- deposited This is especially the case if ARZ is located downstream of ASZ and the test protocol vaπant used is simultaneous, l e the reactant R and the analyte are to migrate into DZ substantially simultaneously In the cases where it is desired to use vaπants that are sequential in the sense that the analyte is to be transported into DZ before the reactant (R), R should be added after the sample has passed ARZ if the application zone for reactant (ARZ) is downstream of ASZ Sequential methods may also be achieved if ARZ is upstream of ASZ, in which case R optionally may be pre-deposited in ARZ In alternative embodiments, reactants (R), for example R*, may migrate into DZ in separate transport flows from another direction than that of the flow that transports the analyte into DZ See, for example, US-A-4,855,240 (Becton & Dickinson)
In one and the same transport flow there may be several detection zones intended for different analytes or different concentration ranges of the same analyte For the case that the analytes are different, the Capturers in the respective DZ must, of course, not exhibit any substantial cross-reactivity against any of the analytes The transport flow from ASZ through the separation zone (SZ) and further to the detection zone (DZ) may be a liquid flow dπven by capillary force When necessary, the flow matπx may exhibit a liquid reservoir (8) in the form of a porous matπx that is soaked with transport liquid and applied upstream of ASZ and/or a sucking porous matπx (9) placed downstream of DZ. The liquid reservoir and the sucking matπx assist in maintaining the flow Liquid flow may also be achieved by means of pressure or suction through the matπx Thus, the pressure may be dπven hydrostatically, for example by a part of the matπx being designed as a mmicolumn placed vertically and with its outlet in direct liquid communication with a hoπzontally located flow matπx In the latter form, the hoπzontally located part of the matrix may be in the form of a stπp/membrane An alternative for transport of analyte, reactants and disturbing components may be the application of an electπc field across the matπx
Similar sequences of zones, like that in Figure 1, may also be constructed for other types of flow matnces, for example capillary tubes and matnces m which the transport flow may be in depth
One or more matπces/ transport flows according to the above may be placed together, for example on a common backing, optionally with a liquid barπer between them Optionally, the flows may have a common ASZ, a common ARZ (AR*Z) etc As a rule, DZ is separate for each transport flow In the above mentioned vaπants. matπces having a separation zone may be used to determine one heteroform (analyte) A matrix without separation zone may be used to determine all heteroforms of the analyte that may be present m the sample in an analogous manner to that for the analyte By combining these two types of zone sequences, relative as well as absolute quantities of analyte in the sample may easily be measured
Separation zone (SZ)
The separation zone exhibits a hgand/structure having binding capability for one or more sample components that would have disturbed the detection in DZ. A characteπstic feature is that the separation is achieved by means of some type of specific/selective binding reaction and not because the matnx m SZ provides a mechanical obstacle for disturbing components (filtration) Guiding pπnciples for the choice of separating/retarding hgand/structure, especially with regard to specificity, binding strength (affinity), and kinetics are the same as in affinity chromatography, including ion-exchange chromatography, covalent chromatography, and biospecific analytical methods in which solid-phase technology is used for capture With regard to binding strength (affinity, avidity) and kinetics, the main object of the presently preferred vaπants of the invention is to retard disturbing components in relation to the analyte so that detection in DZ may take place without presence of these components Generally, this means that the disturbing components should be retarded as effectively as possible or be bound as strongly and quickly as possible m the separation zone The hgands that make separation in SZ possible may thus be a) charged (amonic, catiomc amphoteπc = ion-exchange hgands), amphoteπc/amphiphihc, bioaffine, chelatmg, sulphur-containing (pπmaπly thioether for so-called thiophihc affinity), those permitting covalent chromatography (reactive disulphide such as pyπdyl disulphide) or π-π interaction, hydrophobic etc In those cases where disturbing components are to be retarded, the rule of thumb is that the binding capability of the ligand to one or more disturbing components should be stronger than that to the analyte This applies to the conditions used for the separation in SZ Factors that determine how the separation will succeed are the length of the separation zone, ligand density, ligand availability, temperature, flow velocity, buffer, ion-strength, pH, etc
Among biospecific affinity hgands, pπmaπly so-called immunoligands are noted, l e antibodies and antigen-bmding fragments thereof, and antigen and hapten Other examples of affinity hgands are lectin (for example, siahc acid-bindmg lectms), Ig(Fc)-bmdιng protein (such as Protein A and G), nucleic acid, such as ohgo- or polynucleotide in single or double-stranded form, analogues of substrates for enzymes, enzyme inhibitors, etc For biospecific affinity hgands, the specificity may be directed towards one or more binding sites on the component(s) to be retarded The corresponding binding sites should not be available to the same degree on the analyte (by which is also intended the case that they do not even exist m non-exposed form) The hgands/structures in question may be anchored to the separation zone, either by covalent binding to the matπx, via physical or biospecific adsorption Examples of the latter is the interaction between biotin and streptavidm, between highly affine antibody and hapten etc. The anchorage to the matπx may take place via a polymer or other substituent which in turn carπes covalently, physically adsorptively, or biospecifically bound hgands that are used in the separation Another possibility is deposition of polymeric particles which exhibit a desired type of ligand. The particles may be of hydrophihc or hydrophobic character and to which a compound exhibiting the ligand structure has been adsorbed or covalently bound The technique for binding a separating ligand to the matπx SZ may basically be selected in the same way as previously known for the Capturer in DZ. See, for example, our earlier filed international patent applications PCT/SE98/02462, PCT/SE98/02463 and PCT/SE98/02464 which are hereby incorporated by reference with regard to the introduction of Capturer into the detection zone In this connection it may be mentioned that there are commercially available membranes which have covalently bound hgands, for example DEAE cellulose paper (diethyl ammoethyl) (DE81, Whatman International Ltd, England)
Detection zone
The Capturer m the detection zone may be selected according to the same rules as those applying to the ligand in the separation zone, with the proviso that the binding capability of the Capturer should be directed towards the analyte and/or towards an analyte-related reactant. It is advantageous to choose highly affine Capturers with rapid kinetics for capture of the ligand It is pπmaπly of interest to use antibodies or antigen hapten for which it is often easy to find highly affine antibodies.
By analyte-related reactant is intended a reactant (R) that is added and when migrating through DZ may bind to the Capturer m an amount that is related to the presence of analyte m the sample. Examples of analyte-related reactants are R* in the form of a) labelled analyte analogue m competitive methods that use competition for a limiting amount of solid-phase-bound anti-analyte antibody, and b) labelled or non- labelled soluble anti-analyte antibody m methods that use competition/inhibition between sohd-phase-bound analyte analogue and analyte for a limiting amount of anti- analyte antibody m dissolved form.
The Capturer may be anchored to the detection zone by a technique analogous to that used to bind the ligand to the separation zone It may be suitable to combine a separation principle in the separation zone with a different captuπng pnnciple m the detection zone, e g ion-exchange chromatography for separation and immunochemical adsorption for capture in DZ In some situations it may be practical to use the same pnnciple for retardation and capture in the two zones (e g two monoclonal antibodies having different specificities, see the Examples)
Analyte
By analyte is intended the compound or compounds that are determined quantitatively or qualitatively Quantitative determination relates to the measurement of quantities in absolute as well as relative terms Qualitative determination of an analyte refers to detecting the existence or non-existence of something (yes/no test) or qualitative properties of a compound, such as capability of affimty-bmding to a certain ligand
By relative measurement is intended that the measurement value obtained is a ratio of the sum of one or more selected heteroforms and the sum of another combination of heteroforms An example is the ratio of analyte amount and total amount of all heteroforms with regard to a certain counterpart (total amount includes the amount of analyte)
The invention is applicable to analytes that may function as a binding reactant This means that the analyte basically can be any substance for which it is possible to provide a Capturer as above As specific examples may be mentioned antigen/hapten, enzyme or antibody or nucleic acid which completely or partly are m smgle-stranded form The analyte may exhibit ammo acid/peptide, carbohydrate or hpid structure
Particularly great advantages are obtained for analytes existing together with heteroforms with regard to binding capability to Capturer and/or an added reactant R, for example R* This applies particularly to the cases where the analyte is in sample concentrations which are < 10"7 M, especially < 10~9 M As examples of this type of heteroforms may be mentioned a) Compounds which differ from each other m charge, such as lsotransferπns with, for example, CDT as analyte, isohemoglobins with, for example, HbAlc as analyte, b) Compounds which differ from each other m certain parts of the basic structure, such as additionally inserted or cleaved (e g by degradation) ammo acids, or partial differences in peptide chains, c) Compounds which differ from each other due to the fact that different substances/structures have been added to a basic structure, for example covalently bonded carbohydrate structures, d) macromolecules consisting of two or more subunits which in the macromolecule bind to each other via non-covalent bonds, such as bioaffine bonds between receptor and ligand in receptor- ligand complexes and between antigen and antibody in immunocomplexes, or via cystme bπdges, for example between the chains of an antibody Examples of potential uses/analytes are a) The analyte is a heteroform which differs from other heteroforms with regard to carbohydrate contents (glycosylation), for example glycoproteins having the same or a similar protein part Vaπations m this type of heteroforms are known in a number of disease conditions such as cancer, inflammation and liver diseases (Turner G A, "N- glycosylation of serum proteins m disease and its investigation using lectins", Chn Chim Acta 208 (1992) 149-171, and Varki A, "Biological roles of ohgosacchaπdes all of the theoπes correct", Glycobiology 3(2) (1993) 97-130) Particularly may be mentioned the measurement of I) combinations of asialo-, monosialo- and disialo- transferπn for which separation may be performed by ion-exchange ligand and also by lectm ligand m SZ, and n) HbAlc which may be separated by means of ion-exchange or boronate ligand Variations in the carbohydrate contents of proteins are also known m normal biological changes, for example dunng the menstrual cycle and for differences in age and sex b) The degree of glycosylation of recombinant proteins could be determined by means of ion-exchange, lectm or boronate hgands m SZ The analyte will in this case be the fraction of a recombinant protein that does not contain a carbohydrate structure that binds to the ligand in SZ and therefore migrates most rapidly through SZ c) Recombinant proteins into which a separation handle has been inserted, for example a histidme sequence or an IgG-bmdmg sequence, and where total cleavage of the handle is important, could be checked after separation m SZ by means of a metal chelate ligand or and IgG(Fc)-hgand, respectively The analyte will m this case be the fraction of the recombinant protein from which the histidme sequence or the Ig(Fc)- binding sequence, respectively has been cleaved off d) Enzymes could be separated into an active and an inactive form by means of a ligand in SZ which is a substrate analogue or an inhibitor of the enzyme in question. The analyte will be the inactive enzyme. e) Proteins, peptides or other biomolecules which exert their biological function by binding to a specific receptor could be separated by means of a ligand in SZ which is a receptor for the biomolecule. The analyte will be the fraction of the molecules that lack or have a reduced capability of binding to the receptor. f) Proteins (e.g. IgE) may in vivo have autoantibodies (IgG, IgA, IgM) bound thereto. These autoantibodies give rise to, on the one hand, a differing response in immunochemical determination of the protein, and, on the other hand, an altered turnover rate/function. By using antibodies to the autoantibodies in question as ligand in the separation zone, autoantibodies in free and immunocomplex-bound form may be separated and the amount of the free form of the protein (= analyte, e.g. of IgE) may be calculated. g) By means of a monoclonal antibody directed against a certain binding site of a protein and immobilized to SZ, the presence of heteroforms to the protein which do not exhibit the binding site (= analyte) could detected by quantification in DZ. h) The presence of different substances bound to transport proteins, e.g. a drug bound to albumin, could be measured by using suitable ligands in SZ. By the choice of a suitable ligand in SZ, transport proteins with or without bound drug may be measured in DZ. i) IgG and IgA in serum may in certain rheumatic or autoimmune diseases have an increased adsorption to different surfaces. By anchoring ligands in the separation zone which are capable of binding to IgG and IgA with changed properties, it will be possible to measure the proportion of IgG and IgA with unchanged adsorption properties (= analyte) in DZ. By having the corresponding autoantigen/hapten as Capturer in DZ, specific autoantibodies of IgG or IgA class could be measured with better sensitivity, j) Many biologically active compounds (for example, peptides or steroids) are transported in serum in the form of complexes with binder proteins. By using antibodies against the binder protein as ligand in SZ, the non-complex-bound (free) form of these compounds (= analyte) could be determined immunochemically in the following detection zone. Examples are triiodothyronine and thyroxine which are transported bound to thyroxme-bmdmg globulin (TBG) or thyroxme-binding prealbumm (TBPA) Analogously, free forms of estradiol and testosterone which are transported in bound form with sexual hormone-bindmg globulin may be measured k) The binding capability of a first compound (= analyte) for a second compound may be determined with the invention In this embodiment, one may have the second compound as ligand in SZ, and a Capturer with a known binding capability to the analyte in DZ Capture/retardation m SZ will be a measure of the binding capability of the analyte and may be measured m DZ
This embodiment of the invention may be particularly advantageous in the screening of different libraries of compounds with the library members as ligands m SZ (chemical libraries, for example)
1) Degradation isoforms of proteins where ammo acids have been cleaved off, can be determined by the invention For example, degradation isoforms of creatine kinase (CK) are interesting cardiac markers
Detection in DZ and labelled reactant (R*)
Detection and quantification of signal complexes may be performed by means of an analytically detectable reactant (Reactant* = R*) For those cases where the analyte per se is detectable and is part of a signal complex, detection and quantification may take place without using R*
R* is usually a biospecific affinity reactant which is labelled with an analytically detectable group, such as an enzymatically active group, radioactive group, fluorescent group, chromogemc group, hapten, biotm, particles, etc Analytically detectable reactants (R*) also include reactants which per se have binding sites or properties which may be detected analytically when the reactant is part of the signal complex Examples of such binding sites are Ig-class- and Ig-subclass-specific determinants when the reactant is an antibody and the antigen-binding part thereof is used to form the complex m the detection zone
Usual forms of analytically labelled reactant are labelled antibody and labelled antigen/hapten Labelled antibody has its pπmary use m
A) non-competitive techniques, such as sandwich technique, m which the capturer is a) an antibody which is directed against the same antigen (= analyte) as the labelled antibody, or b) an antigen/hapten, or
B) competitive techniques in which competition takes place between an analyte and a solid phase-bound analyte analogue for a limiting amount of anti-analyte antibody and the detection of free or occupied sites on the solid phase may be performed by means of labelled anti-analyte antibody and anti-anti-analyte antibody, respectively
Labelled antigen hapten has its pπmary use in A) competitive techniques m which a labelled antigen hapten is allowed to compete with an unlabelled antigen/hapten for a limiting amount of antibody
(Capturer), or
B) sandwich-techniques m which antigen/hapten-specific antibody is determined with anti-antibody as Capturer. Examples of vaπants of the invention m which an analytically detectable reactant (R*) is not utilized are those where the analyte per se is detectable when it is part of the complex m DZ This is illustrated with enzyme as analyte m combination with a substrate that gives an analytically detectable product, for example a substrate that gives a coloured or fluorescent product that should be insoluble R* may, but need not, exhibit binding capability to the disturbing components that are separated in SZ To the extent that R* has binding capability, the application zone thereof should be located downstream of the separation zone (SZ), unless it is desired to measure the level of disturbing heteroforms by means of the amount of R* binding to SZ. A particularly useful labelling group is particles which optionally contain one of the above mentioned detectable groups, such as fluorophoπc group or chromogemc group (fluorescent and coloured particles, respectively). Useful particles often have a size in the range of 0 001 to 5 μm, with preference for the range of 0 05 to 5 μm The particles may be of colloidal dimensions, so-called sol (i.e. usually spheπcal and monodisperse having a size in the range of 0.001 to 1 μm). Especially may be mentioned metal particles (for example, gold sol), non-metal particles (for example, SiCb, carbon, latex and killed erythrocytes and bacteπa) Also particles of non-colloidal dimensions have been used These particles have been more or less irregular and more or less polydisperse (for example, carbon particles < 1 μm, Pharmacia AB, WO 96/22532)
When particles are the label group in the invention, the complex in DZ may often be detected visually or by optical measuπng equipment (e g a CCD camera coupled to a computer with special software for image analysis or a laser scanner)
For particles as the label group, it is referred to WO 88/08534 (Unilever), US-A-5, 120,643 (Abbott), EP-A-284,232 (Becton Dickinson) and others
Samples
The invention is primarily intended for biological samples, for example, blood (serum, plasma, whole blood), saliva, tear fluid, uπne, cerebrospinal fluid, sweat, etc The invention is also applicable to other samples, such as fermentation solutions, reaction mixtures, solutions containing a certain protein for which the binding capability to a ligand m SZ is to be investigated, etc See above under the title "Analytes" It may be particularly interesting to use the invention for analysis of environmental samples In addition to the method, the invention also relates to an apparatus and a kit, respectn ely, containing the above defined flow matπx The inventions disclosed in the above-mentioned international applications
PCT/SE98/02462, PCT/SE98/02463 and PCT/SE98/02464 may m relevant parts constitute prefeπed embodiments of the present invention All three applications have been incorporated by reference
PATENT EXAMPLES
EXAMPLE 1. TEST STRIP FOR MEASUREMENT OF THE PROPORTION OF FREE IgE, IgE BOUND TO IgG AND ANTIBODIES TO IgE
In Figures 2A, 2B and 3 the direction of the transport flow is indicated by an arrow (10) In each vaπant there may at the beginning of the transport flow be a zone ASZ (1 1) for sample, downstream thereof a zone DZ (12), at the end of the transport flow a sucking part (13), and between each type of zone, parts which only serve as transport zones (14).
Figure 2A: The variant according to this figure has five separation zones (SZ) in which the ligand may be the same or different or be present in different amounts (15-19) and an AR*Z (20) for reagents.
Figure 2B: This is the same sequence of zones as in Figure 2A except that ASZ (11) and AR*Z (20) coincide (21). This zone sequence may also be used for the cases where the analyte e se is detectable when it is part of a signal complex in DZ. An AR*Z is then not necessary. Figure 3: The sequence of zones according to this figure exhibits two types of separation zones SZ1 (22, 23) and SZ2 (24). respectively, and separately AR*Z (25) downstream of SZ1 (23) and SZ2 (24).
Background: Free IgE and IgE complex-bound to autoantibody (IgA, IgG and IgM) may be of interest to measure. Above all, however, free IgE should be quantified correctly. In the current tests for measurement of IgE, the autoantibodies may bind to the same epitopes on IgE as the reagent antibodies (anti-IgE antibody) and this may then give rise to falsely too low total IgE levels that vary depending on the design of the test. By separating IgG, IgM and IgA before the measurement of IgE, free IgE may be detected. The amount of autoantibodies should also be quantified both as complexes and as free IgG antibodies directed against IgE.
The most common tests measure free antibodies by methods which use IgE bound to a solid phase (corresponding to DZ) with which a heavily diluted serum sample is allowed to interact. If the serum sample contains anti-IgE antibody, the latter is bound to the solid phase forming an immunocomplex. After unbound serum components have been washed away, anti-IgG antibody that is labelled (R*), e.g. with enzyme, is added. Excess of labelled antibody (R*) is removed and the amount of enzyme-labelled anti-IgG antibody (R*) bound to the immobilized immunocomplex is determined by the addition of a suitable substrate. The sensitivity of these tests is limited by the unspecific binding of IgG to the solid phase. The IgE-specific part of the
IgG population is generally very small and may be difficult to distinguish from the amount of unspecifically bound IgG By captuπng IgG to the solid phase and measuπng the binding of IgE, this limitation may be avoided
When measuπng IgG-complex bound IgE, IgG is captured to a solid phase s (corresponding to DZ) which supports covalently bound anti-IgG antibody (Capturer) By adding labelled anti-IgE antibody (R*), the amount of complex-bound IgE may be measured
The use of an immunoassay technique based on lateral liquid transport in membranes as described above where the flow first passes through one or more separation zones (SZ) and then a detection zone (DZ), opens many possibilities for simple measurement of IgE-IgG related parameters If e g a sample that contains a mixture of free IgE and IgE bound to a human anti-IgE antibody of IgG class first is made to pass through a zone containing solid phase-bound anti-human IgG antibody (Ligand in SZ) and then a zone containing solid phase-bound anti-IgE antibody (Capturer in DZ), the sample content of complex between IgE and anti-IgE antibody of IgG class will be bound m the separation zone while free IgE passes to the detection zone where it is determined by adding labelled anti-IgE antibody (R*) upstream of the detection zone (12) but downstream of the separation zones (15-19) for passage only through the detection zone (addition m zone 20 in Fig 2A) By having anti-IgE antibody (R*) pass also the separation zone, the amount of IgE-IgG complex captured m the separation zone by binding to anti-human IgG (Ligand) may also be deteπrnned
(ASZ and AR*Z coincide) (addition m zone 21 m Fig 2B, ASZ common with AR*Z) In the separation zone there are, m addition to complex between IgE and anti-IgE antibody of IgG class, also free antibodies against IgE The amount of the latter may be determined by having labelled IgE (R*j) pass through the separation zone Labelled IgE (R* \ ) is then added m a separate test to the membrane stπp upstream of SZ See Figure
2B
When the amount of IgG is very high in serum, several bands with high concentrations of anti-IgG must be used as SZ Both complex-bound and free anti-IgE antibodies will then be distπbuted over several bands due to the total amount of IgG, and the sum of the signal intensities of these bands gives the amount of antibodies against IgE In the example below, the test principle of artificially prepared complexes of IgE and IgG is demonstrated. The complexes have been prepared with monoclonal antibodies against IgE, and antibodies against mouse-IgG have therefore been bound to the separation membrane. In the detection system, antibodies to IgE directed against other epitopes than the complex-forming antibody have been used. This makes it possible to measure the complex equally well as free IgE in the detection system.
Separation membrane 1 (SZ1): Sheep anti-mouse IgG(Fc) (Ligand 1) was coupled to polystyrene aldehyde particles (0.29 μm diameter, IDC, Portland, Oregon, U.S.A.) by mixing 1.0 mg/ml of antibodies and 20 mg/ml of polystyrene aldehyde particles in 25 mM phosphate buffer, pH 6.6, at +4°C for 20 hours. The particles were washed in 20 mM borate buffer, pH 8.6, and were reacted with 15 mg of NaCNBH3 (Sigma-Aldrich Chemie, Steinheim, Germany) per 50 mg of particles for 20 hours. The particles were then washed in 20 mM borate buffer, pH 8.6, by repeated suspension, centrifugation and decanting. The particle suspension was diluted in 3% trehalose, 20 mM borate buffer, to 25 mg of particles/ml. The diluted suspension was sprayed on strips (20 cm x 3 cm) of membranes of nitrocellulose (nitrocellulose on polyester, 5 μm pore size, Whatman International Ltd, England) in two 0.3 cm wide lines which were parallel to the long sides of the strips. The spraying equipment (IVEK linear striper, IVEK Corporation, Vermont, U.S.A.) delivered about 50 μg of polystyrene particles/cm for each line. The membranes were dried at room temperature and then cut to smaller pieces (0.5 cm x 3 cm).
Separation membrane 2 (SZ2): Mouse IgG (Ligand 2) was diluted in 20 mM borate buffer to 3.4 mg of protein ml. The diluted antibody was sprayed on strips (20 cm x 4 cm) of membranes of nitrocellulose (the same type as above) in a 0.3 cm wide line (spraying equipment as above) with about 6.8 μg of antibodies/cm. The membranes were dried at room temperature and then cut to smaller pieces (0.5 cm x 1 cm).
Detection membrane (DZ): Mouse anti-IgE monoclonal antibody (directed against domain 4 on IgE, Capturer) was diluted in 20 mM borate buffer to 1.0 mg of protein ml. The diluted antibody was sprayed on strips (20 cm x 4 cm) of membranes of nitrocellulose (the same type as above) in a 0.15 wide line (spraying equipment as above) with about 1 μg of antibodies/cm. The membranes were dried at room temperature and then cut to smaller pieces (0.5 cm x 4 cm) so that the line with antibody was parallel with a short side.
Combination membrane: See Figure 3. A piece of separation membrane 1 (0.5 cm x 3 cm, SZ1, 22 and 23, respectively, in Figure 3) were mounted to a piece of separation membrane 2 (0.5 cm x 1 cm. SZ2, 24 in Figure 3) and the thus obtained combined separation membrane was in turn joined to a strip of the detection membrane (0.5 cm x 4 cm, the line = DZ = 12 in Figure 3) (short side to short side with a gap between them). The pieces were kept together on the bottom side by adhesive tape. On the top side were placed pieces of nitrocellulose (0.5 cm x 0.3 cm) (A100, 12 μm, Schleicher and Schull, Dassel, Germany) which somewhat overlapped two adjacent short sides. The latter pieces were kept in place by more adhesive tape. A cellulose filter (13 in Figure 3) (0.5 cm x 2 cm; GB 004, Schleicher and Schull, Dassel, Germany) overlapping the free short side of the detection membrane was mounted as a sucking membrane. The sequence of zones was ASZ, SZ1, SZ2, DZ.
Preparation of carbon particle conjugate (R*):
Carbon suspension (stock solution): 2 g of carbon particles (sp 100, Degussa, Germany) were suspended in 200 ml of 5 mM borate buffer, pH 8.4, and sonicated (VibraCell 600 W, 1.5 cm probe, Soniced Materials, Danebury, Connecticut, U.S.A.) in an ice-bath for 3 x 5 minutes at 100 % amplitude and with 9.9 + 2 seconds pulse. Carbon particle conjugate (R*): 35 μg/ml of Fab '2 of anti-IgE monoclonal antibody (directed against domain 3 in IgE) and a suspension of carbon particles (250 μg /ml) were mixed for 3 hours. Bovine serum albumin (BSA) was added to 1 % and the particles were mixed for another 30 minutes and then washed by means of centrifugation in 1 % BSA (0.1 M borate buffer, pH 8.5, 0.05 % NaN3) and diluted to 0.8 mg carbon ml in the wash buffer. The ready carbon particle conjugate was stored at
+4°C in the wash buffer. Sample material:
Preparation of complex between IgE and IgG 1 mg of IgE (ND)/ml and 5 mg/ml of mouse anti-IgE monoclonal antibody (of IgG class and directed against domain 2) were reacted m 50 mM phosphate buffer, pH 7 5, for 2 75 hours at room temperature The sample mixture (0 35 ml) was separated on Superdex™ 200 prep grade, 16/60 (Amersham Pharmacia Biotech AB, Sweden) The separation gave two discernible complex peaks, one peak corresponded to IgE-IgG and one peak corresponded to IgG- IeE-IgG
Control with 125j_ιabenetι proteins (labelled anti-IgE antibody and labelled IgE):
Separation membrane 1 (Ligand = anti-mouse IgG) Mouse anti IgE antibody (against domain 2 of IgE) and IgE were labelled with *25j (Chloramme T) to a labelling degree of 0 03 for anti-IgE antibody and 1 5 for IgE The labelled proteins were diluted in 6 % BSA (50 mM phosphate buffer, pH 7 5) anti-IgE antibody to about 2 4 μg/ml and IgE to 0 06 μg/ml 125j anti-IgE antibody (domain 2) was mixed with unlabelled anti-IgE antibody (against domain 2) for measuπng higher levels of anti-IgE antibody A sucking membrane (0 5 cm x 2 cm, GB004, Schleicher and Schuell, Dassel, Germany) was attached with tape to one end of a piece of separation membrane 1 (0 5 cm x 4 cm) with adsorbed sheep anti-mouse IgG(Fc) 10 μl of 0 1 M borate buffer, pH 8 5 (6 % BSA, 0 05 % NaN3), followed by 10 μl of a solution of 125I -protein were applied to the free end of the separation membrane The lateral flow was then initiated by the addition of 4 x 10 μl of 0 1 M borate buffer, pH 8 5 (1 % BSA, 0 05 % NaN3) to the free end After all liquid had migrated into the membrane, it was cut to pieces for measurement of the radioactivity in the different zones of the sheet (separation and transport zones) The measurement was made in a gamma counter, and the proportion of 125ι -protein (labelled anti-IgE antibody and labelled IgE, respectively) that had been captured m the different zones was calculated after correction for the amount of free radioactive iodine IgE did not bind any more to the separation zones in which anti-IgG antibody w as the ligand than to the intermediate transport zones More than 85 % IgE passed through the membrane On the other hand, all labelled anti-IgE antibody was bound to the two separation zones when up to 120 ng of anti-IgE antibody were added. When 1000 ng of anti-IgE antibody were added, 200 ng were bound in each anti-mouse IgG zone (separation zone) and 500 ng passed. For IgG in human serum this capacity may be sufficient if the serum is diluted 1/100 (about 1000 ng of IgG) and more anti- IgG antibody (against human IgG) is used as firmly anchored ligand.
Separation membrane 2 (Ligand = mouse IgG): This membrane was introduced to bind any anti-mouse IgG antibody that may have been released from the separation membrane 1 and which otherwise would be bound to the detection zone resulting in an increased background signal (anti-mouse IgG antibody has two Fab parts and may therefore simultaneously bind to R* and Capturer which both are mouse-IgG). The amount of sheep anti-IgG that was released could advantageously be bound with a separation zone containing mouse IgG before the detection zone. By means of this capturing zone (SZ2) the non-specific binding in the detection zone could be reduced by more than 6 times.
Standard protocol for combined separation and immunochemical determination:
20 μl of wash buffer (1 % BSA, 0.9 % NaCl, 1 % Tween 20, 0.1 M borate buffer, pH 8.4, 0.05 % NaN3) were applied to the edge of the free end (ASZ = 11 in Figure 3) of the separation membrane 1 on a combination strip according to the above (Sequence SZl, SZ2, DZ). Then 10 μl of IgE standard (IgE, 4-500 kU/1, 0.01-1.2 μg/ml) and sample (IgE-IgG complex with about 1 μg complex/ml and IgG-IgE-IgG complex with about 1.3 μg complex/ml), respectively, were added. Both sample and standard were diluted in 50 mM phosphate buffer, pH 7.5, containing 6 % BSA and 0.05 % NaN3. A lateral flow was initiated by placing a 0.6 cm x 0.6 cm x 0.3 cm cellulose sponge containing wash buffer, 0.1 M borate buffer, pH 8.4 (1 % BSA, 0.9 % NaCl, 1
% Tween 20, 0.05 % NaN ) on the free end of the separation part of the strip. The test solution migrated through the separation zones (22, 23, 24 in Figure 3) and the detection zone (12 in Figure 3) and into the sucking cellulose sponge (13 in Figure 3). After 7 minutes flow, 10 μl of conjugate (R*) of carbon particles and anti-IgE antibody (0.8 mg carbon/ml in 0.1 M borate buffer, pH 8.4 (1 % BSA, 0.05 % NaN3) were added in the position between the detection zone and the separation part (25) of the strip. After another 5 minutes flow, the detection zone was coloured grey to black The blackening was read in a laser scanner (Ultroscan, Amersham Pharmacia Biotech AB, Uppsala, Sweden), the peak intensity was calculated and the concentration determined by reading against the IgE standard curve The higher the IgE concentration, the blacker the signal As a compaπson, strips having the separation zone 1 replaced by nitrocellulose without ligand (both standard and sample) were evaluated m the same way
Results
The standards (IgE) gave the same intensity on the blackening curve m both measuπng systems The complexes (IgE-IgG and IgG-IgE-IgG) were detected by a strong black signal m DZ if SZ 1 was replaced by nitrocellulose without ligand If SZl contained anti-mouse IgG as ligand, no signal could be detected in DZ for the complexes
Table 1
Sample Separation zone (SZl) Immune complex Without ligand Ligand ■= anti-mouse IgG
IgE-IgG complex 131 kU/1 < 4 kU/1
IgG-IgE-IgG complex 141 kU/1 < 4 kU/1
The separation zone with anti-mouse IgG thus captured up to more than 97 % of the complexes
EXAMPLE 2. DETERMINATION METHOD FOR CD-TRANSFERRIN IN PATIENT SAMPLES
Separation membrane having anion-exchanging properties: A sheet of nitrocellulose membrane (5 μm, nitrocellulose on polyester, Whatman International Ltd, England) was placed m a solution of 0 1 % polyethylene imme (PEI, Sigma, St Louis, MO, U S A ) m ultrapure water (Milh Q, Milhpore Corp , Bedford, MA, U S A ) The solution was shaken for 3 hours and then placed m 0 1 % m Tween 20 for 30 minutes, air-dried and then stored in a plastic bag at +4°C. The modification degree of the membrane was checked with bromophenol blue (pK = 4.1).
The function of modified membranes to interact with charged proteins was confirmed by transporting F25τ_ιabeιιeα' proteins (bovine serum albumin, tetrasialo- and asialo-transferrin which had been labelled by the Chloramine T method) in a lateral liquid flow in strips of the sheet. The protein having the highest pi had the strongest tendency to migrate with the liquid flow. If the liquid in different tests contained an increasing concentration of NaCl (0-1000 mM), the migration rate was affected most for the proteins having the lowest pi. Both these function controls support the fact that positively charged groups had been introduced in the treatment with polyethylene imine, and that these groups can function as ion-exchanging groups towards protein and NaCl.
Detection membrane: Anti-transferrin monoclonal antibody was coupled to polystyrene-aldehyde particles (0.29 μm diameter, IDC, Portland, Oregon, U.S.A.) by mixing 1.3 mg/ml antibody and 22 mg/ml polystyrene-aldehyde particles in 25 mM phosphate buffer, pH 6.6, at +4°C for 18 hours. The particles were washed in 20 mM borate buffer, pH 8.4, and were reacted with 5 mg of NaCNBH3 (Sigma- Aldrich Chemie GmbH, Steinheim, Germany) per 40 mg of particles per ml for 18 hours. The particles were washed in 20 mM borate buffer, pH 8.6, and diluted in 20 mM borate buffer containing 6 % trehalose to 14 mg particles/ml. The diluted suspension was sprayed on strips (20 cm x 4 cm) of membranes of nitrocellulose (5 μm, nitrocellulose on polyester backing, Whatman International Ltd. England) in a 1.4 mm wide line in the middle of the strip and in parallel with the long side of the strip. The spraying equipment was the same as in Example 1 and now delivered 14 μg of polystyrene particles/cm. The membranes were dried at room temperature and stored in a plastic bag at +4°C.
Combination membrane: See Figure 1. The end of a strip of the separation membrane (0.5 cm x 3 cm) (= SZ = 5 in Figure 1) was mounted by means of tape on the underside to the end of a strip of the detection membrane that had been shortened by 0.5 cm (0.5 cm x 3.5 cm, the line with antibody = DZ = 4 in Figure 1). The gap between the ends was bπdged with an overlap by a piece of nitrocellulose membrane (0 3 cm x 0 5 cm, A 100, 12 μm, Schleicher and Schuell, Dassel, Germany) which was kept down by tape As sucking membrane (9 in Figure 1), a cellulose filter (0 5 cm x 2 cm, GB 004, Schleicher and Schuell, Dassel, Germany) was mounted by tape so that it overlapped the free end of the stπp deπved from the detection membrane
Carbon particle conjugate (R*):
Carbon suspension (stock solution) 2 g of carbon particles (sp 4, Degussa, Germany) were suspended in 100 ml of 5 mM borate buffer, pH 8 4, and sonicated with the same apparatus as in Example 1 in an ice-bath for 5 minutes at 100 % amplitude and 5 + 5 seconds pulse
Carbon-particle conjugate 100 μg/ml of anti-transferπn monoclonal antibody and carbon suspension (250 μg/ml) were mixed for 2 hours BSA was added to 1 % and the particles were mixed for another 30 minutes and then washed by means of centπfugation in O l M borate buffer, pH 8 5 (containing 1 % BSA and 0 05 % NaN3) and diluted to 1 9 mg carbon/ml with wash buffer The ready carbon particle conjugate was stored at +4°C in wash buffer
Sample materials: Tetrasialo-transfernn Tetrasialo-transferπn was isolated from an iron-saturated preparation of human transferπn (mainly tetrasialo-transfernn) by ion-exchange chromatography on Mono Q (Amersham Pharmacia Biotech AB, Uppsala, Sweden)
Asialo-transfernn An iron-saturated preparation of transferπn (Sigma, St Louis, MO, USA) was treated with neuramidase (Behπngwerke, Marburg, Germany), whereupon asialo-transferπn was isolated by ion-exchange chromatography on Mono Q
(Amersham Pharmacia Biotech AB, Uppsala, Sweden)
Isoelectnc points (pi) These values were determined for the respective isoform preparation and for BSA by isoelectnc focusing m Phast System (Amersham Pharmacia Biotech AB, Uppsala, Sweden) Asialo-form pi = 5 7, tetrasialo-form pi = 5 3 and bovine serum albumin pi = 4 7 Transferrin standard: Asialo-transferrin prepared as above was diluted in 20 mM BIS-TRIS pH 6.3 containing 0.2 % BSA, 0.1 % Tween 20, 0.1 mM Fe3+-citrate, 1 mM NaHC0 and 0.05 % NaN3 to the concentrations 0.07-16.6 μg transferrin/'ml and was used as standard. Serum samples: 11 serum samples and 6 serum controls were diluted 1/50 in 20 mM BIS-TRIS pH 6.3 containing 0.1 % bovine gammaglobulin (Sigma, St Louis, U.S.A.), 0.1 % Tween 20, 0.1 mM Fe3+-citrate, 1 mM NaHC0 , and 0.05 % NaN3. The serum samples were previously analysed with regard to CDT by means of CDTect (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). CDTect measures CD- transferrin.
Standard protocol for combined separation and immunochemical determination: 2 μl of sample (dilution series of transferrin and diluted serum samples, respectively) were applied at 1 cm from the edge (ASZ = 3 in Figure 1) of the free end of the membrane part with separation zone on a combination strip according to the above. A lateral liquid flow was initiated by placing a 0.6 cm x 0.6 cm x 0.3 cm cellulose sponge (8 in Figure 1) soaked with 20 mM BIS-TRIS buffer, pH 6.5, containing 15 mM NaCl and 0.1 % Tween 20 on the free end of the separation zone. In the separation zone (5 in Figure 1) the analyte (CD-transferrin) and its heteroforms (other transferrins) are attracted by positive charges firmly anchored in the zone (Ligand introduced in the PEI treatment) so that a heteroform having a greater negative charge (other transferrins) is attracted more than a heteroform having a smaller negative charge (CD-transferrin), i.e. CD- transferrins migrate easier with the liquid flow than trisialo-, tetrasialo-, pentasialo- etc transferrin. During its migration through the combination strip/matrix, a certain proportion of the total amount of transferrin will therefore be able to bind to the anti- transferrin antibody (Capturer) in the detection zone (DZ = 4 in Figure 1). After 4 minutes flow, 5 μl of conjugate (R*) between carbon particles and anti-transferrin antibody (1.8 mg carbon ml in 0.1 M borate buffer, pH 8.4, containing 30 % trehalose, 1 % Tween 20, 1 % BSA, 0.05 % NaN3) were added between the separation zone and the detection zone (in zone (6) in Figure 1 (= AR*Z)). After another 5 minutes, the flow was stopped and the blackening in the detection zone was read with a laser scanner (Ultroscan, Amersham Pharmacia Biotech AB, Uppsala, Sweden) and the concentration was calculated by reading against measurement values for the dilution series of asialo- transferrin. The higher the level of CD-transferrin is in the sample, the stronger is the blackening signal.
Table 2: Results
Figure imgf000030_0001
The measurement values obtained with the method of the invention showed very good conformity with those obtained with CDTect (correlation coefficient 0.971 ). The invention is considerably faster and simpler to perform than CDTect.
EXAMPLE 3. TEST STRIP WITH SAMBUCUS NIGRA LECTIN IN THE SEPARATION ZONE
Separation membrane: A sheet (4 cm x 12 cm) of cellulose (cellulose filter 54, Whatman International Ltd, England) was activated with cyano-diethyl-aminopyridine (CDAP) (Kohn and Wilchek, Appl. Biochem. Biotechnol. 9 (1984) 285-304). The activated sheet was placed in a solution of 0.1 mg/ml of Sambucus Nigra lectin (binds sialic acid which is in the terminal position of a carbon chain; Vector Laboratories Inc., Burlingame. CA, U.S.A.) in 0.1 M NaHC03, pH 8.4. The solution was shaken for 2 hours, and the sheet was then placed in a) 0.1 M NaHC03, b) 0.5 M NaCl, c) distilled water, d) 0.1 M acetate buffer, pH 4.5, e) 0.1 M NaHC0 , pH 8.4, f) 0.5 M NaCl, g) distilled water, h) 0.1 M acetate buffer, pH 4.5, i) 5 mM BIS-TRIS, pH 6.4, containing 0.1 % Tween 20. Between the different baths, excess liquid was sucked off by means of kitchen roll paper. After the wash procedure, the sheet was air-dried and stored in a plastic bag at +4°C.
Before the sheet was used, the sheet was mounted to self-adhering plastic (75 μm self-adhering polyester film; Gelman Science Inc, Ann Arbor, MI, U.S.A.).
Membranes with detection zone and combination strip: These membranes can be produced in analogy with Example 2. See also Figure 1. The ligand in SZ is now lectin.
Carbon-particle conjugate (R*) and 125j_ιa eue(j proteins. See Example 2.
Control of separation membrane by means of 125i-iabelled proteins: Tetrasialo- and asialo-transferrin and bovine albumin were labelled with 125τ (Chloramine T, labelling degree 0.08-0.13). The labelled proteins were diluted in 10 mM BIS-TRIS pH 6.4 containing 0.1 % Tween 20, 0.04 mM Fe3+-citrate and 0.05 % NaN3 to about 0.3 μg/ml. Additionally, 0.4 mg BSA/ml was added. A (0.5 cm x 4 cm) strip of the separation membrane and a piece of a sucking membrane of cellulose (0.5 cm x 2 cm, GB004, Schleicher and Schuell, Dassel, Germany) were joined by tape on the underside so that their ends overlapped somewhat. 1 μl of the solutions of the 125j_ιabeιιecj proteins were applied at 1 cm from the free end of a respective separation membrane. The lateral flow was initiated by placing a cellulose sponge (0.6 cm x 0.6 cm x 0.3 cm) on the free end of the separation membrane. The sponge was soaked with 20 mM TRIS-HCL buffer, pH 7.5, containing 0.5 M NaCl, 1 mM CaCl2 with 0.1 % Tween 20. The flow was interrupted by removing the cellulose sponge after 2, 4, 6 and 10 minutes, respectively, and the membranes were cut 2 and 3 cm from the free end of the separation membrane. The radioactive membrane pieces were measured in a gamma counter and the proportion of added 125j_ protein that had passed 2 and 3 cm was calculated. The values for migration of 1 cm or more is shown in Table 4.
Table 4. % of totally added 125j_prolem that had migrated more than 1 cm in the separation membrane:
Figure imgf000032_0001
Conclusion: It appears from the results that tetrasialo-transferrin is heavily retarded in the separation membrane by the Sambucus Nigra lectin, while asialo-transferrin and BSA are not retarded to the same extent. The results indicate that a separation membrane with Sambucus Nigra lectin may be combined with a detection membrane in analogy with Example 2 and be used for quantifying CD-transferrin in samples containing transferrin with a greater content of sialic acid than CD-transferrin.

Claims

1. A method of determining an analyte in a sample by means of binding reactions, which method comprises: i. applying the sample to an application zone for sample (ASZ) on a flow matrix in which transport of components present in the sample may take place (transport flow), the flow matrix further comprising: a) optionally an application zone (AR*Z) for a binding reactant (Reactant* = R*) which is analytically detectable, b) a detection zone (DZ) which is located downstream of ASZ and comprises another binding reactant (Capturer) firmly anchored to the matrix and in which a complex (signal complex) containing the Capturer and the analyte and/or Reactant* is formed during the method, and ii. detecting the signal complex in the detection zone, the measured signal being used for determining the analyte, characterized in that the flow matrix comprises at least one separation zone (SZ) between ASZ and DZ and that this zone (SZ) exhibits a structure (ligand) having binding capability for either (i) at least one component other than the analyte which is transported in the matrix and which would affect the measurable signal if the component is transported into DZ, so that said component(s) substantially does (do) not disturb the detection of the analyte in DZ, or (ii) the analyte, and the binding capability of the ligand for the analyte is determined.
2. The method according to claim 1, characterized in that said component is a heteroform to the analyte with regard to binding capability for the Capturer and/or R*.
3. The method according to claim 1 or 2, characterized in that the transport flow is driven by capillary forces.
4. The method according to any one of claims 1-3, characterized in that at least
DZ and the most adjacent parts of the matrix are in the form of a membrane, and that the transport flow at least into, in and out of DZ is lateral.
5. The method according to any one of claims 1-4, characterized in that the separation zone exhibits a Ligand which is charged and attracts said component.
6. The method according to any one of claims 1-4, characterized in that the separation zone exhibits a Ligand which has biospecific affinity directed towards said component.
7. The method according to any one of claims 1-4 and 6, characterized in the separation zone exhibits a Ligand which has immunochemical affinity (i.e. the structure (ligand) is an antibody or an antigen/hapten) against said component.
8. The method according to any one of claims 1-7, characterized in that said component is not the analyte and that the binding capability of the ligand is to a binding site on said component, and that this binding site is not available to the same degree on the analyte.
9. The method according to any one of claims 1-8, characterized in that said component is not the analyte and that the Capturer in the detection zone exhibits binding capability to a binding site on the analyte which also is available on said component.
10. The method according to any one of claims 1-9, characterized in that said component is not the analyte and that Reactant* is used and has binding capability to a binding site which is available on a) both the analyte and said component, or b) only on the analyte.
11. The method according to any one of claims 1-10, characterized in that the analyte and said component are heteroforms which differ with regard to carbohydrate structure.
12. A test kit for determining an analyte in a sample without other components disturbing the determination, which kit comprises
A. a flow matrix which in one and the same transport flow comprises: a) an application zone for sample containing the analyte (ASZ), b) a detection zone (DZ) in which there is a biospecific affinity reactant (Capturer), which is directed towards the analyte or towards an analyte-related reactant and which is firmly anchored to the matrix in DZ,
B. optionally an analytically detectable reactant (Reactant* = R*) having biospecific affinity to either the analyte or the Capturer, characterized in that the flow matrix comprises a separation zone (SZ) between
ASZ and DZ, which zone exhibits a structure (ligand) having binding capability for at least one disturbing component, SZ being capable of affecting substantially all of said disturbing component.
13. The test kit according to claim 12, characterized in that at least DZ and the most adjacent parts of the matrix are in the form of a membrane and that the direction of the transport flow at least into, in and out of DZ is lateral.
14. The test kit according to any one of claims 12-13, characterized in that the transport channels of the flow matrix have capillary dimensions, i.e. are of such a form and surface character that aqueous media can be transported by capillary forces.
15. The test kit according to any one of claims 12-14, characterized in that the structure (ligand) has binding capability to disturbing components originating from the sample, usually heteroforms to the analyte with regard to binding capability to the Capturer and or R*.
16. The test kit according to any one of claims 12-15, characterized in that the structure (ligand) exhibits one or more positive and/or negative charges at the conditions under which the matrix is to be used.
17. The test kit according to any one of claims 12-15, characterized in that the structure (ligand) is a biospecific affinity reactant, for example an antibody or an antigen or a hapten.
18. The test kit according to any one of claims 12-17, characterized in that the
Capturer is a biospecific affinity reactant, for example an antibody or an antigen or a hapten.
19. The test kit according to any one of claims 12-18, characterized in that the kit comprises an analytically detectable reactant R*, that the flow matrix comprises an application zone for R* (AR*Z) and that AR*Z is located upstream and/or downstream of SZ but always upstream of DZ.
20. The test kit according to claim 19, characterized in that AR*Z is located upstream of, downstream of, or coincides with ASZ.
21. The test kit according to any one of claims 19-20, characterized in that R* is pre-deposited in AR*Z.
22. A test kit for determining the binding capability of a structure (ligand) to an analyte, which kit comprises
A. a flow matrix which in one and the same transport flow comprises: a) an application zone for the analyte (ASZ), b) a detection zone (DZ) in which there is a biospecific affinity reactant (Capturer), which is directed towards an analyte or towards an analyte-related reactant and which is firmly anchored to the matrix in DZ, B) optionally an analytically detectable reactant (Reactant* = R*) having biospecific affinity to either the analyte or the Capturer, characterized in that the flow matrix comprises a separation zone (SZ) between ASZ and DZ, which zone exhibits said structure (ligand).
PCT/SE1999/000722 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing analytes WO1999060402A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69936916T DE69936916T2 (en) 1998-04-30 1999-04-30 LIGANDEN BINDING TEST AND KIT WITH A SEPARATION ZONE FOR DISTURBING SAMPLE COMPONENTS
CA2330100A CA2330100C (en) 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing analytes
JP2000549963A JP4579414B2 (en) 1998-04-30 1999-04-30 Kit with ligand binding assay and inhibitory analyte separation region
AU43036/99A AU758583B2 (en) 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing analytes
US09/673,882 US6737278B1 (en) 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing analytes
EP99952122A EP1075661B1 (en) 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing sample components

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801563A SE9801563D0 (en) 1998-04-30 1998-04-30 Method of separation and kit to be used in the process
SE9801563-9 1998-04-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/673,882 A-371-Of-International US6737278B1 (en) 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing analytes
US10/633,653 Division US20040023412A1 (en) 1998-04-30 2003-08-05 Ligand binding assay and kit with a separation zone for disturbing analytes

Publications (1)

Publication Number Publication Date
WO1999060402A1 true WO1999060402A1 (en) 1999-11-25

Family

ID=20411187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/000722 WO1999060402A1 (en) 1998-04-30 1999-04-30 Ligand binding assay and kit with a separation zone for disturbing analytes

Country Status (10)

Country Link
US (2) US6737278B1 (en)
EP (2) EP1075661B1 (en)
JP (1) JP4579414B2 (en)
AT (1) ATE371189T1 (en)
AU (1) AU758583B2 (en)
CA (1) CA2330100C (en)
DE (1) DE69936916T2 (en)
ES (1) ES2293736T3 (en)
SE (1) SE9801563D0 (en)
WO (1) WO1999060402A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036418A1 (en) * 1998-12-11 2000-06-22 Axis-Shield Asa Dipstick for carbohydrate-free transferrin assay
WO2008153462A1 (en) * 2007-06-14 2008-12-18 Maiia Ab Determination of isoerythropoietins
US7723124B2 (en) 2004-02-09 2010-05-25 Rapid Pathogen Screening, Inc. Method for the rapid diagnosis of targets in human body fluids
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
EP2618152A1 (en) 2012-01-20 2013-07-24 Ortho-Clinical Diagnostics, Inc. Assay device having controllable sample size
US8609433B2 (en) 2009-12-04 2013-12-17 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with sample compressor
US8669052B2 (en) 2008-06-10 2014-03-11 Rapid Pathogen Screening, Inc. Lateral flow nucleic acid detector
US8815609B2 (en) 2008-05-20 2014-08-26 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with diverting zone
US8962260B2 (en) 2008-05-20 2015-02-24 Rapid Pathogen Screening, Inc. Method and device for combined detection of viral and bacterial infections
US9068981B2 (en) 2009-12-04 2015-06-30 Rapid Pathogen Screening, Inc. Lateral flow assays with time delayed components
US9121849B2 (en) 2008-06-10 2015-09-01 Rapid Pathogen Screening, Inc. Lateral flow assays
WO2016205637A2 (en) 2015-06-18 2016-12-22 Neurological Surgery, P.C. Detection of cerebrospinal fluid
US10379121B2 (en) 2008-05-20 2019-08-13 Rapid Pathogen Screening, Inc. Method and device for combined detection of viral and bacterial infections
US10808287B2 (en) 2015-10-23 2020-10-20 Rapid Pathogen Screening, Inc. Methods and devices for accurate diagnosis of infections
US11016090B2 (en) 2011-01-18 2021-05-25 Symbolics, Llc Lateral flow assays using two dimensional features

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767710B2 (en) * 2001-03-30 2004-07-27 Praxsys Biosystems, Llc Prewetting stop flow test strip
US7605004B2 (en) * 2001-07-18 2009-10-20 Relia Diagnostic Systems Llc Test strip for a lateral flow assay for a sample containing whole cells
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
ATE502300T1 (en) * 2002-12-26 2011-04-15 Nitto Boseki Co Ltd IMMUNOASSAY PROCEDURE
US8101429B2 (en) * 2003-06-03 2012-01-24 Siemens Healthcare Diagnostics Inc. Native analyte as a reference in lateral flow assays
EP1733232A1 (en) * 2004-03-23 2006-12-20 Quidel Corporation Hybrid phase lateral flow assay
ATE479096T1 (en) * 2004-07-29 2010-09-15 Relia Diagnostic Systems Llc CROSS-FLOW SYSTEM AND ASSAY
US7465587B2 (en) * 2004-12-03 2008-12-16 Genzyme Corporation Diagnostic assay device
US8389209B2 (en) 2005-12-08 2013-03-05 Coris Bioconcept Test device for rapid diagnostics
US7794656B2 (en) * 2006-01-23 2010-09-14 Quidel Corporation Device for handling and analysis of a biological sample
US7871568B2 (en) * 2006-01-23 2011-01-18 Quidel Corporation Rapid test apparatus
US20080138842A1 (en) * 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
US20100105071A1 (en) * 2007-02-28 2010-04-29 Children's Medical Center Corporation Methods for predicting the onset of menarche
US8501495B2 (en) * 2007-05-03 2013-08-06 Equal Access To Scientific Excellence Sequential solid phase immunoassay including contact pad to limit conjugate flow during manufacture
ES2355299T3 (en) * 2007-07-20 2011-03-24 Université De Liége COMBINED METHOD FOR THE SEQUENTIAL MEASUREMENT OF (1) THE ENZYMATICALLY ACTIVE FRACTION AND (2) THE TOTAL AMOUNT OF AN ENZYME.
WO2009034563A2 (en) * 2007-09-14 2009-03-19 Nanocomms Patents Limited An analysis system
US8021873B2 (en) 2008-07-16 2011-09-20 Boston Microfluidics Portable, point-of-care, user-initiated fluidic assay methods and systems
CA2758526A1 (en) * 2009-04-15 2010-10-21 Relia Diagnostic Systems, Inc. Diagnostic devices and related methods
US8168396B2 (en) 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
WO2010144507A2 (en) * 2009-06-08 2010-12-16 Acrotech Systems Inc. Rapid detection of cerebrospinal fluid, methods and systems therefore
EP2490800A4 (en) * 2009-10-20 2013-05-01 Boston Microfluidics Methods and systems to collect and prepare samples, to implement, initiate and perform assays, and to control and manage fluid flow
JP5847158B2 (en) 2010-04-07 2016-01-20 バイオセンシア パテンツ リミテッド Flow control device for assays
JP6012052B2 (en) * 2010-10-01 2016-10-25 ホロジック, インコーポレイテッドHologic, Inc. Immunoassay test strips for use in diagnostic systems
US10739337B2 (en) * 2011-08-30 2020-08-11 Board Of Trustees Of Michigan State University Extraction and detection of pathogens using carbohydrate-functionalized biosensors
CN104823046A (en) * 2012-08-08 2015-08-05 保罗·桑德斯 Compact multiple media chromatography
AU2014232782B2 (en) 2013-03-15 2018-05-24 Hycor Biomedical, Inc. Device and associated methods for performing luminescence and fluorescence measurements of a sample
CN103278637B (en) * 2013-06-05 2015-09-30 姜竹泉 A kind of carbon nano-tube Test paper detecting helicobacter pylori and preparation method thereof
US20170089893A1 (en) * 2015-09-24 2017-03-30 Globallergy, Llc Chromatographic immune assay for the detection of allergic sensitivities
US11579145B2 (en) 2016-10-17 2023-02-14 Reliant Immune Diagnostics, Inc. System and method for image analysis of medical test results
US11802868B2 (en) 2016-10-17 2023-10-31 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results
US11693002B2 (en) 2016-10-17 2023-07-04 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type
US11107585B2 (en) 2016-10-17 2021-08-31 Reliant Immune Diagnostics, Inc System and method for a digital consumer medical wallet and storehouse
US12009078B2 (en) 2016-10-17 2024-06-11 Reliant Immune Diagnostics, Inc. System and method for medical escalation and intervention that is a direct result of a remote diagnostic test
US11651866B2 (en) 2016-10-17 2023-05-16 Reliant Immune Diagnostics, Inc. System and method for real-time insurance quote in response to a self-diagnostic test
US10902951B2 (en) 2016-10-17 2021-01-26 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
US9857372B1 (en) 2016-10-17 2018-01-02 Reliant Immune Diagnostics, LLC Arbovirus indicative birth defect risk test
EP4071476A1 (en) * 2018-02-14 2022-10-12 Salignostics Ltd. Methods and apparatus for detecting analytes

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378391A2 (en) * 1989-01-10 1990-07-18 Biosite Diagnostics Inc. Threshold ligand-receptor assay
EP0696735A1 (en) * 1994-08-08 1996-02-14 Quidel Corporation Controlled sensitivity immunochromatographic assay
EP0702233A1 (en) * 1993-06-02 1996-03-20 Teikoku Hormone Mfg. Co., Ltd. Simple immunochemical semiquantitative assay method and apparatus
WO1996022532A1 (en) * 1995-01-20 1996-07-25 Pharmacia Ab Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles
US5541069A (en) * 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
GB2300914A (en) * 1995-04-28 1996-11-20 Tepnel Medical Ltd Analyte detection device for liquid samples
WO1997035205A1 (en) * 1996-03-20 1997-09-25 Serex, Inc. Chromatographic immunoassay device and method utilizing particle valency for quantitation
WO1998036278A1 (en) * 1997-02-15 1998-08-20 Beth Israel Deaconess Medical Center, Inc. Multiple-site antibody capture immunoassays and kits
WO1998057172A1 (en) * 1997-06-11 1998-12-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3445816C1 (en) * 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flat diagnostic agent
US4740468A (en) 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
CA1303983C (en) 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
EP0560411B1 (en) 1987-04-27 2000-07-26 Unilever N.V. Specific binding assays
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US5451504A (en) * 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
US5356782A (en) * 1992-09-03 1994-10-18 Boehringer Mannheim Corporation Analytical test apparatus with on board negative and positive control
US5766552A (en) * 1993-04-20 1998-06-16 Actimed Laboratories, Inc. Apparatus for red blood cell separation
WO1997034148A1 (en) * 1996-03-14 1997-09-18 Spectral Diagnostics, Inc. Immunoassay device
US20020081629A1 (en) * 2000-06-30 2002-06-27 Tibotec N.V. Apparatus for the simultaneous transfer of liquid analytes
US20040137608A1 (en) * 2002-11-27 2004-07-15 Aaron Garzon Chemical microarrays and method for constructing same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378391A2 (en) * 1989-01-10 1990-07-18 Biosite Diagnostics Inc. Threshold ligand-receptor assay
US5541069A (en) * 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
EP0702233A1 (en) * 1993-06-02 1996-03-20 Teikoku Hormone Mfg. Co., Ltd. Simple immunochemical semiquantitative assay method and apparatus
EP0696735A1 (en) * 1994-08-08 1996-02-14 Quidel Corporation Controlled sensitivity immunochromatographic assay
WO1996022532A1 (en) * 1995-01-20 1996-07-25 Pharmacia Ab Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles
GB2300914A (en) * 1995-04-28 1996-11-20 Tepnel Medical Ltd Analyte detection device for liquid samples
WO1997035205A1 (en) * 1996-03-20 1997-09-25 Serex, Inc. Chromatographic immunoassay device and method utilizing particle valency for quantitation
WO1998036278A1 (en) * 1997-02-15 1998-08-20 Beth Israel Deaconess Medical Center, Inc. Multiple-site antibody capture immunoassays and kits
WO1998057172A1 (en) * 1997-06-11 1998-12-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716641B1 (en) 1998-12-11 2004-04-06 Axis-Shield Asa Dipstick for carbohydrate-free transferrin assay
WO2000036418A1 (en) * 1998-12-11 2000-06-22 Axis-Shield Asa Dipstick for carbohydrate-free transferrin assay
US7723124B2 (en) 2004-02-09 2010-05-25 Rapid Pathogen Screening, Inc. Method for the rapid diagnosis of targets in human body fluids
US10001482B2 (en) 2004-02-09 2018-06-19 Quidel Corporation Device for the detection of an analyte in a fluid sample
US8647890B2 (en) 2004-02-09 2014-02-11 Rapid Pathogen Screening, Inc. Method for the rapid diagnosis of targets in human body fluids using undiluted samples
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
US9250236B2 (en) 2005-02-09 2016-02-02 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
WO2008153462A1 (en) * 2007-06-14 2008-12-18 Maiia Ab Determination of isoerythropoietins
US8962260B2 (en) 2008-05-20 2015-02-24 Rapid Pathogen Screening, Inc. Method and device for combined detection of viral and bacterial infections
US10408835B2 (en) 2008-05-20 2019-09-10 Rapid Pathogen Screening, Inc. Method and device for combined detection of viral and bacterial infections
US10379121B2 (en) 2008-05-20 2019-08-13 Rapid Pathogen Screening, Inc. Method and device for combined detection of viral and bacterial infections
US8815609B2 (en) 2008-05-20 2014-08-26 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with diverting zone
US9121849B2 (en) 2008-06-10 2015-09-01 Rapid Pathogen Screening, Inc. Lateral flow assays
US8822151B2 (en) 2008-06-10 2014-09-02 Rapid Pathogen Screening, Inc. Lateral flow nucleic acid detector
US8669052B2 (en) 2008-06-10 2014-03-11 Rapid Pathogen Screening, Inc. Lateral flow nucleic acid detector
US8609433B2 (en) 2009-12-04 2013-12-17 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with sample compressor
US9068981B2 (en) 2009-12-04 2015-06-30 Rapid Pathogen Screening, Inc. Lateral flow assays with time delayed components
US9939434B2 (en) 2009-12-04 2018-04-10 Rapid Pathogen Screening, Inc. Multiplanar lateral flow assay with sample compressor
US11016090B2 (en) 2011-01-18 2021-05-25 Symbolics, Llc Lateral flow assays using two dimensional features
EP2618152A1 (en) 2012-01-20 2013-07-24 Ortho-Clinical Diagnostics, Inc. Assay device having controllable sample size
CN103212454A (en) * 2012-01-20 2013-07-24 奥索临床诊断有限公司 Assay device having controllable sample size
US10712340B2 (en) 2012-01-20 2020-07-14 Ortho-Clinical Diagnostics, Inc. Assay device having controllable sample size
US11921107B2 (en) 2012-01-20 2024-03-05 Ortho-Clinical Diagnostics, Inc. Assay device having controllable sample size
EP3311142A4 (en) * 2015-06-18 2018-12-12 Neurological Surgery, P.C. Detection of cerebrospinal fluid
CN107850548A (en) * 2015-06-18 2018-03-27 神经外科公司 The detection of cerebrospinal fluid
WO2016205637A2 (en) 2015-06-18 2016-12-22 Neurological Surgery, P.C. Detection of cerebrospinal fluid
US11067581B2 (en) 2015-06-18 2021-07-20 Nspc Technologies, Llc Detection of cerebrospinal fluid
US10808287B2 (en) 2015-10-23 2020-10-20 Rapid Pathogen Screening, Inc. Methods and devices for accurate diagnosis of infections

Also Published As

Publication number Publication date
SE9801563D0 (en) 1998-04-30
EP1075661A1 (en) 2001-02-14
CA2330100A1 (en) 1999-11-25
AU758583B2 (en) 2003-03-27
ES2293736T3 (en) 2008-03-16
AU4303699A (en) 1999-12-06
US20040023412A1 (en) 2004-02-05
ATE371189T1 (en) 2007-09-15
JP4579414B2 (en) 2010-11-10
DE69936916T2 (en) 2008-05-15
EP1075661B1 (en) 2007-08-22
DE69936916D1 (en) 2007-10-04
CA2330100C (en) 2011-08-09
EP1467210A1 (en) 2004-10-13
US6737278B1 (en) 2004-05-18
JP2002516393A (en) 2002-06-04

Similar Documents

Publication Publication Date Title
CA2330100C (en) Ligand binding assay and kit with a separation zone for disturbing analytes
DK172179B1 (en) Test method and reagent kit thereto
US5521102A (en) Controlled sensitivity immunochromatographic assay
KR920005963B1 (en) Method for the determination of a specific binding substance
AU2007319076B2 (en) Saturation assay
EP0303110A2 (en) Immunodiagnostic device and method
WO2001050129A2 (en) Compensation for non-specific signals in quantitative immunoassays
EP0243370A1 (en) Determination of clinical parameters by enzyme immunoprocess
EP0564494B1 (en) Test method and reagent kit therefor
US4865997A (en) Assay for ligands by separating bound and free tracer from sample
AU592971B2 (en) Solid phase diffusion assay
US4138213A (en) Agglutination immunoassay of immune complex with RF or Clq
EP0641388B1 (en) Ion-capture assays using a binding member conjugated to carboxymethylamylose
JPWO2005015217A1 (en) Measuring object measuring instrument, measuring apparatus and measuring method
JPH11133023A (en) Compound for reducing influence of urea on chromatographic immunoassay using urine sample
US5382530A (en) Method for the quantitative determination of a free form of substances present in biological fluids
AU2003200222B2 (en) Ligand binding assay and kit with a separation zone for disturbing analytes
EP0141620B1 (en) Specific binding assay reagent
US20030073126A1 (en) Competitive immunoassay using complexed analyte derivatives02
Keating et al. Immunoassay for the determination of 7-hydroxycoumarin in serum using'real-time'biosensor analysis
JP2729917B2 (en) Method of measuring analyte free portion in biological fluid
AU2014200264A1 (en) Saturation assay

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999952122

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 43036/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2330100

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09673882

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999952122

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 43036/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999952122

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999952122

Country of ref document: EP